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Introduction
During the last decades, the advancements in micro- and nano- technology have brought
tremendous encouragement to the current biomedical research. Porous silicon (pSi) has
many interesting properties that are being investigated for diverse biomedical applications,
including biomolecular screening, optical biosensoring, drug delivery through injectable
carriers and implantable devices, and orally administered medications with improved bio-
availability (1,2). There are already several FDA-approved and marketed products based on
pSi technology that have found a niche in ophthalmology and another product, based on
radioactive 32P-doped pSi, is currently in clinical trials, as a potential new brachytherapy
treatment for inoperable liver cancer.
Targeted delivery could offer significant toxicity reduction in adjuvant or neo-adjuvant
cancer therapies. Our research group has designed and developed a multistage nanocarrier
based on the pSi technology, with the potential to overcome the multiple biological barriers
encountered in the circulation and efficiently deliver therapeutics to the tumor site (3).
Hemispherical disk-shaped particles with a diameter of 1–3 μm have been chosen to
enhance the specific recognition and adhesion to vascular targets based on the theory of
Decuzzi et al. (4) and Sakamoto et al. (5). Also, the pSi particle (first stage) has been shown
to effectively load multiple types of smaller nanoparticles (second stage), such as quantum
dots and single-wall carbon nanotubes, thus originating a multistage delivery system (3).
The mechanism of action of the multistage system is schematically presented in Figure 1 (3).
Biocompatibility and biodegradability are the key requirements for any drug delivery
carrier. Moreover, in the multistage system biodegradation plays an important role in
delivering second-stage nanoparticles to the target site. In the present study we aimed at
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Fabrication and Surface Modification of the Particles
pSi particles were fabricated from P++-doped wafers with a resistivity of 0.0008–0.005
Ohm-CM by electrical-chemical etching, as previously described (3). The physical
dimensions and pore sizes of the particles were verified by high-resolution SEM, and the
surfaces were oxidized in a piranha solution, resulting in oxidized particles. The positively
charged particles were produced by the introduction of amine groups on the surface by
silanization with 0.5% (vol/vol) 3-aminopropyltriethoxysilane (APTES) in isopropanol at
room temperature. PEG-NHS with different lengths was further conjugated to the APTES-
modified particles.
Biodegradation Study
Mesoporous silicon particles with different pore sizes and surface modifications were tested.
The particles were incubated in PBS (pH 7.4) or fetal bovine serum (FBS) for up to 72 hr.
The samples were collected at various time points and processed for ICP-AES analysis of
silicic acid, which is the degradation product of pSi in the medium, and for SEM analysis of
particle morphology.
Biocompatibility Evaluation
THP-1 human monocytes, J774 murine macrophages, and human umbilical vein endothelial
cells (HUVEC) were purchased from ATCC and Lonza. THP-1 monocytes were
differentiated into macrophages in 24-well dishes for 48–96 hr with 5–80 ng/mL of phorbol
ester PMA. The cells were washed and incubated with oxidized, APTES-modified, and
PEGylated particles for up to 48 hr. Zymosan particles were used as a positive control of
cytokine production. The cell culture supernatant samples were collected at 1, 4, 8, 24, and
48 hr. Production of pro-inflammatory cytokines, IL-6 and IL-8, in the supernatants were
determined by commercial ELISA kits. Phagocytosis of the particles with various surface
modifications was evaluated using J774 macrophages for 4 hr, followed by processing and
SEM analysis.
Whole mouse blood, collected following a cardiac puncture, was used to evaluate the
compatibility of the systems with erythrocytes. The 107–108 particles/mL of blood were
incubated at 37°C, using a rotary shaker for up to 5 hr. The blood was then centrifuged, and
the plasma was collected and analyzed for iron content, using ICP-AES as an indicator of
hemolysis.
Results and Discussion
Two independent methods, ICP-AES and SEM analysis, have shown that surface
modifications, as well as the porosity of the particle, affect the rate of degradation and, as a
result, the amount of silicon deposited in solution in both physiological solutes (Figure 2).
The degradation is complete when the concentration of silicon in the solution, as analyzed
by ICP-AES, reaches a plateau. The particles conjugated to higher molecular weight PEGs
and having small pore sizes exhibit degradation kinetics at a much slower rate.
Fine control of the degradation, which impacts the release kinetics of nanoparticles and
drugs from the mesoporous silicon structures, is of fundamental importance in the
development of multistage and multifunctional delivery systems. pSi microcarriers can be
administered systemically and used to deliver a payload of a different nature (therapeutic,
imaging, or both). The size of the pores and surface chemistry of the pSi structure can be
controlled during the fabrication process and thereafter. Our data point toward the possibility
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to control degradation of mesoporous silicon microparticles and devices by means of
particle morphology, porosity, and PEGylation and may have important clinical
implications.
Internalization of the pSi multistage particles by murine and human immune cells can be
controlled by means of particle surface modifications (Figure 3). PEGylation prevents
particles from being internalized by macrophages. No significant release of proinflammatory
cytokines were observed when the immune and endothelial cells were incubated with
mesoporous silicon multistage carriers, as can be seen in Figure 4 for release of IL-6 from
HUVEC and THP1 cells. Similar results were obtained for various other cytokines in
THP-1, HL60 (differentiated human neutrophils), J774 (murine macrophages), Jurkat (T
cells), and HU-VEC cells.
The results of incubation of the carrier with whole blood show that the particles did not
induce erythrocyte lysis, since plasma content of iron was not different from the untreated
control.
Conclusions
The results of this study show that 1) the multistage delivery carrier is biocompatible with
immune cells, endothelial cells, and erythrocytes; and 2) the degradation profile of pSi
structures could be modulated as a function of morphology and surface modifications. is
unique multistage system, composed of mesoporous silicon particles able to carry a payload
of various nanoparticles, is currently being investigated for targeted delivery of therapeutics
and imaging agents to the tumor site.
Acknowledgments
The study was supported by the following grants: DoDW81X-WH-04-2-0035 Project 16; NASA SA23-06-017;
State of Texas, Emerging Technology Fund; DoD W31P4Q-07-1-0008; and NIH 1R01CA128797-01. The authors
would like to recognize the contributions and support from the Alliance for NanoHealth (ANH).
References
1. Salonen J, Kaukonen AM, Hirvonen J, Lehto VP. Mesoporous silicon in drug delivery applications.
J Pharm Sci. 2008; 97:632–653. [PubMed: 17546667]
2. Stewart MP, Buriak JM. Chemical and biological applications of porous silicon technology. Adv
Mater. 2000; 12:859–869.
3. Tasciotti E, Liu X, Bhavane R, Plant K, Leonard A, Price B, Cheng MC, Decuzzi P, Tour J,
Robertson F, Ferrari M. Mesoporous silicon particles as a multistage delivery system for imaging
and therapeutic applications. Nat Nanotech. 2008; 3:151–157.
4. Decuzzi P, Lee S, Bhushan B, Ferrari M. A theoretical model for the margination of particles within
blood vessels. Ann Biomed Eng. 2005; 33:179–190. [PubMed: 15771271]
5. Sakamoto J, Annapragada A, Decuzzi P, Ferrari M. Antibiological barrier nanovector technology
for cancer applications. Expert Opin Drug Deliv. 2007; 4:359–369. [PubMed: 17683250]
Godin et al. Page 3














Schematic presentation of the mechanism of action of multistage pSi nanovectors (3). The
multistage delivery system is assembled by loading second-stage nanoparticles (Q-dots and
SWNTs, micelles, liposomes, etc.) into the pores of mesoporous silicon microparticles.
After intravenous injection, the rationally designed multistage system travels through the
blood stream and, as a result of its unique size, shape, and chemical modifications, avoids
RES uptake, interaction with red blood cells, and finally, migrates to the vessel wall
(margination), where it adheres to the target endothelium. Multistage microparticles release
their payload, which penetrates through the fenestrations of the target vasculature and
eventually diffuses into the tissue surrounding the vessel. Second-stage nanoparticles are
then taken up by the cells, where they accomplish their tasks.
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Degradation of pSi particles with different surface modifications over time: quantification of
the particle degradation product, silicic acid, released to the degradation medium by ICP-
AES.
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Internalization of (A) PEGylated (PEG MW 5,000 Da) and (B) APTES pSi particles by J744
murine macrophages following 4 hr of incubation.
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Release of IL-6, a proinflammatory cytokine, by endothelial HUVEC cells and THP-1
human macrophages following incubation with PEGylated and non-PEGylated multistage
pSi particles compared with untreated cells (control) and a positive control, zymosan
particles that induce cytokine release.
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